Collegium Pharmaceutical, Inc COLL
Collegium Pharmaceutical, Inc (Nasdaq: COLL) is a pain/anesthesia drug developer. Its lead program, Commercial portfolio (Jornay PM, Azstarys, Belbuca, Xtampza ER, Nucynta, Symproic), is marketed for ADHD and moderate to severe pain.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Jornay PM (methylphenidate HCl) | ADHD | small molecule | Approved |
| Azstarys (serdexmethylphenidate/dexmethylphenidate) | ADHD | small molecule | Approved |
| Belbuca (buprenorphine buccal film) | Severe persistent pain | small molecule | Approved |
| Xtampza ER (oxycodone ER, abuse-deterrent) | Severe persistent pain | small molecule | Approved |
| Nucynta ER / Nucynta IR (tapentadol) | Pain | small molecule | Approved |
| Symproic (naldemedine) | Opioid-induced constipation | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.